Kamada
KMDA • NASDAQ
Kamada is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Amir London, with a market cap of $470.1M.
CEOAmir London
Next Earnings
Upcoming earnings announcement for Kamada
Date
Wednesday, May 13, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.12
Revenue Estimate
$105.3M
Earnings History
Past 12 earnings reports for Kamada
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | Q4 2025 | $0.06Est: $0.08 | -25.0% | $44.7MEst: $104.8M | -57.4% | — |
| Nov 10, 2025 | Q3 2025 | $0.09Est: $0.10 | -10.0% | $47.0MEst: $110.7M | -57.5% | — |
| Aug 13, 2025 | Q2 2025 | $0.13Est: $0.09 | +44.4% | $38.4MEst: $111.9M | -65.7% | — |
| May 14, 2025 | Q1 2025 | $0.07Est: $0.07 | 0.0% | $44.0MEst: $41.8M | +5.3% | — |
| Mar 5, 2025 | Q4 2024 | $0.07Est: $0.05 | +40.0% | $39.0MEst: $39.5M | -1.1% | — |
| Nov 13, 2024 | Q3 2024 | $0.07Est: $0.07 | 0.0% | $41.7MEst: $40.9M | +2.0% | — |
| Aug 14, 2024 | Q2 2024 | $0.08Est: $0.06 | +33.3% | $42.5MEst: $39.7M | +7.0% | — |
| May 8, 2024 | Q1 2024 | $0.04Est: $0.06 | -33.3% | $37.7MEst: $38.0M | -0.7% | — |
| Mar 6, 2024 | Q4 2023 | $0.09Est: $0.05 | +80.0% | $36.4MEst: $37.7M | -3.4% | — |
| Nov 13, 2023 | Q3 2023 | $0.06Est: $0.03 | +100.0% | $37.9MEst: $37.5M | +1.1% | — |
| Aug 16, 2023 | Q2 2023 | $0.04Est: $0.02 | +100.0% | $37.4MEst: $34.2M | +9.6% | — |
| May 24, 2023 | Q1 2023 | -$0.04Est: $0.02 | -300.0% | $30.7MEst: $34.3M | -10.5% | — |